Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciprofloxacin Prophylaxis for Meningococcal Meningitis Contacts
NCT02724046Phase 4Completed
- Sponsor
- Illumina
- Start
- Apr 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ciprofloxacin in meningococcal meningitis (3 arms), sponsored by Illumina. Primary endpoint: Meningitis Attack Rate at 3 months. Started Apr 2017; status: completed.
02
Drugs
ciprofloxacin
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT02724046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02724046.